What's Happening?
Guided Therapeutics has reported a revenue of $0.767 million for 2025, a significant increase from the previous year's $0.007 million. This growth is attributed to increased device shipments and the recognition of deferred revenue related to China. Despite
the revenue increase, the company reported a net loss per share of $(0.04), with a total net loss of $(3.196) million. The company's operating expenses rose to $2.943 million, contributing to a loss from operations of $(2.372) million. The company is focusing on market expansion in the U.S., China, and Europe, with ongoing regulatory reviews and potential approvals anticipated in 2026.
Why It's Important?
The financial results highlight Guided Therapeutics' efforts to expand its market presence and increase revenue through international shipments and regulatory progress. The company's ability to secure FDA clearance and expand into new markets like China and Europe could significantly impact its financial performance and investor confidence. The ongoing losses and increased operating expenses underscore the challenges faced by the company in scaling its operations and achieving profitability.
What's Next?
Guided Therapeutics plans to submit its FDA pivotal trial results in Q2 2026, with potential approval in China expected by Q3 2026. The company's focus on expanding its market presence in the U.S., China, and Europe will be critical in driving future revenue growth. The outcome of regulatory reviews and the company's ability to manage manufacturing and quality challenges will be key factors in its future success.
